Journal
Cancers
Publication Date
9-10-2025
Volume
17
Issue
18
First Page
2961
Document Type
Open Access Publication
DOI
10.3390/cancers17182961
Rights and Permissions
Kumar A, Tohmasi S, Eaton DB Jr, Seyoum N, Brandt WS, Thomas TS, Schoen MW, Rossetti NE, Chang SH, Yan Y, Patel MR, Malone S, Tokaz MC, Meyers BF, Kozower BD, Puri V, Heiden BT. Real-World Adoption of Adjuvant Therapies for Resected Stage IB-III Non-Small-Cell Lung Cancer. Cancers (Basel). 2025 Sep 10;17(18):2961. doi: 10.3390/cancers17182961 Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/ licenses/by/4.0/).
Recommended Citation
Kumar, Arvind; Tohmasi, Steven; Seyoum, Nahom; Brandt, Whitney S; Thomas, Theodore S; Rossetti, Nikki E; Chang, Su-Hsin; Yan, Yan; Meyers, Bryan F; Kozower, Benjamin D; Puri, Varun; Heiden, Brendan T; and et al., "Real-world adoption of adjuvant therapies for resected stage IB-III non-small-cell lung cancer." Cancers. 17, 18. 2961 (2025).
https://digitalcommons.wustl.edu/oa_4/5464
Department
ICTS (Institute of Clinical and Translational Sciences)
